Following these transactions, Gilson holds 9,582 shares of Arcellx common stock. The sale included broker-assisted transactions to cover tax liabilities associated with the acquisition of restricted stock units. The company maintains a strong financial position with a current ratio of 4.29, indicating sufficient liquidity to meet short-term obligations. For deeper insight into Arcellx’s financial health and additional metrics, investors can access the comprehensive Pro Research Report available at InvestingPro. The company maintains a strong financial position with a current ratio of 4.29, indicating sufficient liquidity to meet short-term obligations. For deeper insight into Arcellx’s financial health and additional metrics, investors can access the comprehensive Pro Research Report available at InvestingPro.
Additionally, on January 8, 2025, Gilson conducted another sale of shares totaling $654,065, with prices ranging from $73.6929 to $75.5283. These transactions were part of a 10b5-1 trading plan, which was originally established on December 18, 2023 and later amended on March 27, 2024. Despite the recent price movements, analysts maintain price targets in the range of $104 to $134 for the stock.
Following these transactions, Gilson holds 9,582 shares of Arcellx common stock. The sale included broker-assisted transactions to cover tax liabilities associated with the acquisition of restricted stock units.
In other recent news, Arcellx Inc. saw a number of positive developments, with various companies maintaining their buy ratings and raising their price targets. Stifel and TD Cowen highlighted the potential of Arcellx’s candidate, anito-cel, in the multiple myeloma market, with Stifel reiterating its Buy rating and $122.00 price target. BofA Securities increased its target price to $112 from the previous $100, maintaining a Buy rating, following the release of iMMagine-1 interim key data for anito-cel. Truist Securities echoed that sentiment, raising its price target to $136 from $87 previously, citing Arcellx’s strong financial position and promising data for Anito-cel.
Piper Sandler maintained an Overweight rating and raised its price target to $115 after Arcellx’s Q3 2024 earnings report. The companies noted significant results from clinical studies of anito-cel for relapsed or refractory multiple myeloma, with the Phase 1 study showing a median progression-free survival of 30.2 months, and the phase 2 study of iMMagine-1 showed an overall response rate of 95%.
Arcellx’s manufacturing capabilities for anito-cel were also praised, potentially giving it a significant advantage in the cancer treatment market. These recent developments are driven by the progress of Arcellx and the upcoming release of full data from the iMMagine-1 study for anito-cel.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
